Loading...
Docoh

Design Therapeutics (DSGN)

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

DSGN stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$16.00
Low target
$6.00
High target
$26.00
Wedbush
Maintains
Outperform
$26.00
9 Aug 22
Goldman Sachs
Maintains
Sell
$6.00
24 May 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 22
11 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 119.65M 119.65M 119.65M 119.65M 119.65M 119.65M
Cash burn (monthly) 55.89M 20.93M 5.21M 4.29M 3.5M 3.31M
Cash used (since last report) 78.35M 29.34M 7.31M 6.01M 4.91M 4.64M
Cash remaining 41.31M 90.31M 112.35M 113.64M 114.75M 115.01M
Runway (months of cash) 0.7 4.3 21.6 26.5 32.8 34.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jun 22 Heather Behanna Stock Option Common Stock Grant Acquire A No No 13.69 15,000 205.35K 15,000
15 Jun 22 Deepa Prasad Stock Option Common Stock Grant Acquire A No No 13.69 15,000 205.35K 15,000
15 Jun 22 George Simeon Stock Option Common Stock Grant Acquire A No No 13.69 15,000 205.35K 15,000
15 Jun 22 Arsani William Stock Option Common Stock Grant Acquire A No No 13.69 15,000 205.35K 15,000
15 Jun 22 Schmid John P. Stock Option Common Stock Grant Acquire A No No 13.69 15,000 205.35K 15,000
91.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 65 63 +3.2%
Opened positions 6 16 -62.5%
Closed positions 4 5 -20.0%
Increased positions 30 29 +3.4%
Reduced positions 16 5 +220.0%
13F shares Current Prev Q Change
Total value 940.59M 1.1B -14.8%
Total shares 51.09M 49.47M +3.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
SR One Capital Fund I Aggregator 5.63M $166.09M 0.0%
SR One Capital Management 5.63M $90.87M 0.0%
Cormorant Asset Management 5.16M $83.29M -5.2%
Irrevocable Trust #1 dated April 22, 2019 Light 3.83M $82.09M 0.0%
Irrevocable Trust #1 dated April 22, 2019 Star 3.83M $82.09M 0.0%
BLK Blackrock 3.15M $50.89M +42.2%
Logos Global Management 2.8M $45.18M +0.9%
Citadel Advisors 2.53M $40.94M 0.0%
EcoR1 Capital 2.37M $38.3M +10.1%
Avoro Capital Advisors 2.22M $35.89M +35.8%
Largest transactions Shares Bought/sold Change
BLK Blackrock 3.15M +935.2K +42.2%
Avoro Capital Advisors 2.22M +586.12K +35.8%
Cormorant Asset Management 5.16M -283.46K -5.2%
Hillhouse Capital Advisors 0 -280.99K EXIT
BCS Barclays 226.51K +226.51K NEW
EcoR1 Capital 2.37M +218.45K +10.1%
TROW T. Rowe Price 574.01K -213.65K -27.1%
Norges Bank 0 -200K EXIT
JHG Janus Henderson 1.12M +181.78K +19.4%
Wellington Management 999.17K +143.64K +16.8%

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: April, ATM, Connecticut, effectuate, fourth, landscape, reliant, shelf
Removed: elderly, GeneTAC, half, reserve, sheet